Ford Marvella, Wahlquist Amy, Blake Rashell, Green CoDanielle, Streets June, Fuller Ebonie, Johnson Erica, Jefferson Melanie, Etheredge James, Varner Heidi, Johnson Shannon, Glover Saundra, Turner David, Garrett-Mayer Elizabeth
Medical University of South Carolina, Vorhees College, USA.
Prog Community Health Partnersh. 2012 Fall;6(3):249-63. doi: 10.1353/cpr.2012.0038.
African Americans (AA) are not well-represented in cancer clinical trials despite having significantly higher cancer mortality rates than their European-American (EA) counterparts.
The purpose of this study was to evaluate a program to improve perceptions of cancer clinical trials among AA.
The program was conducted in a convenience sample of 195 participants (75.4% AA) who lived in counties with high racial disparities in cancer mortality rates and who were recruited by community partners. The 30-minute program, part of a larger 3.5-hour cancer education program, was developed by the National Institutes of Health (NIH)/National Cancer Institute (NCI). It was modified to include additional pictures of AA, AA-specific cancer mortality data, and information about the Tuskegee Syphilis Study and the resulting improved participant protection measures.
The seven-item Attitudes to Randomized Trial Questionnaire (ARTQ) was used to evaluate changes in trial perceptions from pre- to posttest. Additional survey items assessed general demographic characteristics.
Slightly more than half of the participants had at least a college diploma (54.4%), 45.1% were married/living as married, 53.3% were female, and 45.6% had an annual household income of less than $40,000. For each ARTQ item, most participants who had less favorable perceptions of trials at pretest changed to more positive perceptions at posttest (p < .001).
Providing cancer clinical trial information led to more positive perceptions of cancer clinical trials. In future studies, the program could be used to help potential trial participants make informed decisions about participation; trial enrollment rates could then be evaluated.
非裔美国人(AA)在癌症临床试验中的代表性不足,尽管他们的癌症死亡率明显高于欧裔美国人(EA)。
本研究的目的是评估一项旨在改善非裔美国人对癌症临床试验看法的项目。
该项目在195名参与者(75.4%为非裔美国人)的便利样本中进行,这些参与者居住在癌症死亡率存在高度种族差异的县,由社区合作伙伴招募。这个30分钟的项目是美国国立卫生研究院(NIH)/国立癌症研究所(NCI)开发的一个更大的3.5小时癌症教育项目的一部分。它经过修改,增加了非裔美国人的额外图片、特定于非裔美国人的癌症死亡率数据,以及关于塔斯基吉梅毒研究和由此产生的改进后的参与者保护措施的信息。
使用七项随机试验态度问卷(ARTQ)来评估从测试前到测试后对试验看法的变化。其他调查项目评估一般人口统计学特征。
略多于一半的参与者至少拥有大学文凭(54.4%),45.1%已婚/以已婚状态生活,53.3%为女性,45.6%的家庭年收入低于4万美元。对于ARTQ的每个项目,大多数在测试前对试验看法不太积极的参与者在测试后转变为更积极的看法(p <.001)。
提供癌症临床试验信息导致对癌症临床试验有更积极的看法。在未来的研究中,该项目可用于帮助潜在的试验参与者就是否参与做出明智的决定;然后可以评估试验入组率。